VG-161

N/A

Report date: 2026/04/24 20:01:59

Base Information

Drug NameVG-161
Drug Alias NameRecombinant Human IL12/15-PDL1B Oncolytic HSV-1 InjectionRecombinant Human IL12/15-PDL1B Herpes Simplex Type I Oncolytic VirusVG-161
ClassificationBiologics > Oncolytic virus
Mechanisms of ActionInterleukin-12 stimulantsInterleukin-15 stimulants
TargetsInterleukin-12Interleukin-15
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursUrinary Bladder Neoplasms +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesCnbg-Virogin Biotech (Shanghai) Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesFudan University Shanghai Cancer CenterVirogin Biotech Canada LtdViroGin Biotech Ltd +[5] 
Inactive CompaniesN/A
Active IndicationsGastroesophageal Junction NeoplasmsSolid tumoursUrinary Bladder Neoplasms +[10] 
Inactive IndicationsEsophageal NeoplasmsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A